Shares of PTC Therapeutics, Inc. (PTCT) are declining more than 34 percent on Friday morning trade after the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has given a negative opinion to its conditional authorization and full marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RTW Investments LP increased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 26.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,093,298 shares of the biopharmaceutical company’s stock after acquiring an additional 1,477,911 shares during the quarter. PTC Therapeutics […]
RTW Investments LP boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 26.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 7,093,298 shares of the biopharmaceutical company’s stock after purchasing an additional 1,477,911 shares during the period. PTC Therapeutics comprises approximately 7.2% of RTW Investments LP’s investment portfolio, […]
/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy. Through the.